LTAS
NVCR icon

Linden Thomas Advisory Services’s NovoCure NVCR Stock Holding History

Linden Thomas Advisory Services’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,126
Closed -$205K – 472
2024
Q1 		$205K Buy
13,126
+89
+0.7% +$1.31K 0.03% 439
2023
Q4 		$195K Buy
13,037
+88
+0.7% +$1.18K 0.04% 411
2023
Q3 		$209K Buy
+12,949
New +$373K 0.05% 374

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Linden Thomas Advisory Services's NVCR Position: Q2 2024 in Review

Linden Thomas Advisory Services sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 13,126 shares — an estimated $205K sold.

Linden Thomas Advisory Services first reported a position in NVCR in Q3 2023 and held it in 3 quarters. The position peaked at $209K in Q3 2023. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • Linden Thomas Advisory Services reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 13,126 NovoCure shares in Q2 2024, an estimated $205K.
  • Linden Thomas Advisory Services first reported a position in NovoCure in Q3 2023 and held it in 3 quarters.
  • Linden Thomas Advisory Services's NovoCure position peaked at $209K in Q3 2023.
  • 236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2024, filed 10 Jul 2024.